PECAM1 and COVID-19: In the group of post-COVID-19 patients, values of those respective parameters were comparable to patients with ASCVD without significant differences, except for IMT of the axillary artery, which was lower (p = 0.017), and for CD31+/CD42b– EMP, which were higher (p = 0.012) in the COVID-19 group.